Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as valaciclovir HCl granules
valaciclovir granules · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| valaciclovir HCl granules | DRUG | - |
Inclusion criteria: * Subjects aged 1 year to less than 12 years with a clinical diagnosis of chickenpox within 48 hours of the onset of the rash. Exclusion criteria: * History of hypersensitivity reactions. * Impaired hepatic or renal function. * Gastrointestinal dysfunction. * Serious underlyin...
Valaciclovir granules are an antiviral treatment being studied for varicella, commonly known as chickenpox. The granules are an oral formulation developed for patients with this infectious disease. GSK plc is the company developing the product, which has completed a Phase 3 trial in patients with chickenpox.
Valaciclovir granules are developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating the granules in varicella. The product is an oral small molecule antiviral formulation.
Valaciclovir granules are in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and has not been approved by the FDA for varicella.
The valaciclovir granules program includes one completed Phase 3 trial, NCT00169416, titled Evaluation Of Valaciclovir In Patients With Chickenpox. The trial enrolled 43 patients with varicella, including children as young as 1 year old, and was an uncontrolled study.
Yes, valaciclovir granules are also known as valaciclovir HCl granules. Both names refer to the same GSK plc product being developed for varicella. The HCl form is the hydrochloride salt of valaciclovir used in the granule formulation.